In Focus this month:
Global Epidemiology Study Shows Resistance to Tenofovir
(From: The Lancet Infectious Diseases)
This collaborative study showed that the prevalence of HIV drug resistance against the commonly used antiretroviral drug tenofovir is far higher than expected, especially in sub-Saharan Africa. The authors recommended optimizing treatment and surveillance, since tenofovir is the "backbone" drug recommended by the World Health Organization for people starting HIV treatment.
Preexposure Prophylaxis Revolution
(From: Current Opinion in HIV & AIDS)
This editorial summarized opportunities and challenges of pre-exposure prophylaxis (PrEP) as a new prevention tool that promises significant contributions to global HIV programs. The authors said that since implementation is just beginning, programs should consider offering PrEP first to high-risk individuals who already know that they need more protection than is currently available.
Combination Social Protection Significantly Reduces HIV Risk Behavior amongst Adolescents in South Africa
(From: Journal of Acquired Immune Deficiency Syndromes)
This study found that social protection interventions are more effective when implemented in combination than alone. Appropriate combinations of cash transfers, free schooling, school feeding, parental monitoring, and teacher support have the potential to reduce adolescents' risks of HIV.